Lonza Trims Portfolio To Nutrition, Pharma, Biotech; Equity Groups Acquire Specialty Business
Executive Summary
Private equity firms Bain Capital and Cinven Group Ltd. agree to acquire Lonza’s specialty ingredients business for $4.72Bn. Lonza says it will focus on its pharma, biotech and nutrition business, including a nutraceutical capsule manufacturing operation.
You may also be interested in...
People On The Move: Appointments At GSK, Karo And Lonza
The latest European consumer health industry appointments: GSK names Sheppard as DACH head; Karo hires GSK’s Hale as CMO; and Lonza brings in Novartis’ Deecke as CFO.
US FDA Adds Hand Sanitizer Import Alert Category After COVID-19 Production Surge Turned Deadly
Action responds to methanol contamination in hand sanitizers manufactured in Mexico and marketed in the US under numerous brands that followed a loosening standards for the products to drive a swift increase in production and meet surging demand during the coronavirus pandemic.
US Consumers' Hand Sanitizer Resources Expand: FDA Allows Compounding During Pandemic
Agency says compounding pharmacies are more familiar with standards and methods for producing drug products than “untrained consumers.” It will allow operations that might otherwise get sanctioned for marketing adulterated drugs because their products likely are better than some remedies consumers are making. It is aware consumers are experiencing difficulties accessing alcohol-based hand sanitizers and are concocting their own hand sanitizers.